TriangleNCT01801436 · OUTCOME
Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Hours
- Interval / dispersion
- Standard Deviation
- Time frame
- 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
What was measured
The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
Analysis population: The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.
Groups in this outcome
Bortezomib
Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
| Group | Source count |
|---|---|
| Bortezomib | 10 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bortezomib | 0.08 | 0.07 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.07
- value
- 0.08
- denoms
- counts
- group Id
- OG000
- value
- 10
- units
- Participants
- description
- The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
- id
- OG000
- title
- Bortezomib
- param Type
- MEAN
- population Description
- The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.
- reporting Status
- POSTED
- time Frame
- 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
- title
- Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1
- type
- PRIMARY
- unit Of Measure
- Hours
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice